Veradermics (MANE) Cash from Operations (2025 - 2026)
Veradermics' (MANE) quarterly Cash from Operations came in at 21200000.0 in Q1 2026, down 59.4% YoY from 52214814.81 in Q1 2025, and down 59.4% on a QoQ basis from 13300000.0 in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Cash from Operations (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Cash from Operations data on file, last reported at 21200000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | -14.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.50 Mn |
| Mar 31, 2026 | -21.20 Mn |
| Jun 30, 2025 | -15.68 Mn |
| Mar 31, 2025 | -13.32 Mn |